Peak Retirement Planning Inc. Invests $1.06 Million in Insulet Co. (NASDAQ:PODD)

Peak Retirement Planning Inc. bought a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,070 shares of the medical instruments supplier's stock, valued at approximately $1,063,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in Insulet during the 4th quarter valued at approximately $248,806,000. Raymond James Financial Inc. acquired a new position in Insulet during the 4th quarter valued at approximately $69,433,000. Alecta Tjanstepension Omsesidigt acquired a new position in Insulet during the 4th quarter valued at approximately $53,184,000. Artisan Partners Limited Partnership increased its stake in Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after purchasing an additional 149,524 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Insulet by 20.5% during the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after purchasing an additional 125,710 shares in the last quarter.

Insulet Stock Performance

NASDAQ PODD traded down $3.09 during mid-day trading on Wednesday, reaching $323.55. 919,836 shares of the stock were exchanged, compared to its average volume of 709,521. The business's 50 day moving average is $273.47 and its 200-day moving average is $270.65. Insulet Co. has a 1 year low of $171.61 and a 1 year high of $333.24. The company has a market capitalization of $22.77 billion, a P/E ratio of 55.88, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 earnings per share. On average, equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. Oppenheimer upped their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Barclays increased their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Royal Bank of Canada initiated coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective on the stock. Wall Street Zen lowered shares of Insulet from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and a consensus target price of $309.88.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.